Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab plus bendamustine in relapsed follicular lymphoma
jRCTs041190084Phase 2Active, not recruiting
- Sponsor
- Nippon Shinyaku
- Start
- Mar 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obinutuzumab and bendamustine in follicular lymphoma (FL), sponsored by Nippon Shinyaku. Primary endpoint: 3-year progression-free survival. Started Mar 2020; status: active, not recruiting.
02
Drugs
obinutuzumabbendamustine
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on jRCTs041190084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041190084.